Literature DB >> 7332730

Pharmacokinetics of phenytoin in children.

P G Blain, J C Mucklow, C J Bacon, M D Rawlins.   

Abstract

1 Apparent Vmax and Km for phenytoin were estimated in 40 children (aged 8--33 months) and 21 adults (aged 18--66 years). 2 The derived values of Vmax and Km were used to predict the plasma and salivary concentrations of phenytoin following a change in dose. There was a highly significant correlation between observed and predicted steady-state concentration in both children and adults (P less than 0.001). 3 The apparent Km was similar in children (7.5 +/- 1.2 mg/l) and adults (9.4 +/- 2.3 mg/l). 4 Vmax differed significantly (P less than 0.001) between children (20.4 +/- 2.1 mg kg-1 day-1) and adults (8.7 +/- 0.7 mg kg-1 day-1). 5 After correction for differences in the ratio of liver weight to body weight in children and adults, Vmax was similar in the two groups.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7332730      PMCID: PMC1401952          DOI: 10.1111/j.1365-2125.1981.tb01285.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Management of seizure disorders with anticonvulsant drugs: current concepts.

Authors:  P H Berman
Journal:  Pediatr Clin North Am       Date:  1976-08       Impact factor: 3.278

2.  Human brain, cerebrospinal fluid, and plasma concentrations of diphenylhydantoin and phenobarbital.

Authors:  F Vajda; F M Williams; S Davidson; M A Falconer; A Breckenridge
Journal:  Clin Pharmacol Ther       Date:  1974-06       Impact factor: 6.875

3.  Rapid determination of diphenylhydantoin in blood plasma by gas-liquid chromatography.

Authors:  J MacGee
Journal:  Anal Chem       Date:  1970-03       Impact factor: 6.986

4.  Optimal phenytoin therapy: a new technique for individualizing dosage.

Authors:  P W Mullen
Journal:  Clin Pharmacol Ther       Date:  1978-02       Impact factor: 6.875

5.  The clinical pharmacokinetics of phenytoin.

Authors:  E Martin; T N Tozer; L B Sheiner; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

6.  Individualization of phenytoin dosage regimens.

Authors:  T M Ludden; J P Allen; W A Valutsky; A V Vicuna; J M Nappi; S F Hoffman; J E Wallace; D Lalka; J L McNay
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

Review 7.  Clinical pharmacokinetics of phenytoin.

Authors:  A Richens
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

  7 in total
  6 in total

Review 1.  Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.

Authors:  James H Fischer; Tejal V Patel; Patricia A Fischer
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Population pharmacokinetics of phenytoin in Singapore Chinese.

Authors:  E Chan; T Y Ti; H S Lee
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Steady-state pharmacokinetics of phenytoin from routinely collected patient data.

Authors:  T H Grasela; L B Sheiner; B Rambeck; H E Boenigk; A Dunlop; P W Mullen; J Wadsworth; A Richens; T Ishizaki; K Chiba
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

4.  Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients.

Authors:  L A Bauer; R A Blouin
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

6.  Intravenous phenytoin: a retrospective analysis of Bayesian forecasting versus conventional dosing in patients.

Authors:  Andrea Tobler; Stefan Mühlebach
Journal:  Int J Clin Pharm       Date:  2013-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.